Recurrent Symptomatic Hemorrhage in Cerebral Cavernous Malformations After Discontinuation of Atorvastatin or Placebo

Background A recent randomized prospective controlled trial demonstrated that atorvastatin for up to 2 years was safe but did not significantly alter rebleeding in cerebral cavernous malformations. However, any consequences of discontinuing atorvastatin remain unknown. We hypothesized that symptomat...

Descripció completa

Dades bibliogràfiques

Autors principals:	Bader Ali, Robert Shenkar, Justine Lee, Roberto J. Alcazar‐Felix, Richard E. Thompson, Agnieszka Stadnik, Georgio Sader, Sean P. Polster, Kelly D. Flemming, James K. Liao, Matthew Sorrentino, Romuald Girard, Daniel F. Hanley, Issam A. Awad
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2026-02-01
Col·lecció:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Matèries:	atorvastatin bleeding cessation discontinuation rebound effect statin
Accés en línia:	https://www.ahajournals.org/doi/10.1161/JAHA.125.046943
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!